Females with salt-wasting (SW) 21-hydroxylase deficiency (21OHD) may present with mild external genitalia virilization, despite complete or almost complete enzyme inactivation. We therefore analyzed genotype/phenotype correlation in 13 Japanese female patients with SW 21OHD. Criteria for classification into the SW phenotype included history of a salt-losing crisis with documented hyponatremia, hyperkalemia, and markedly elevated plasma renin activity. Urologists and pediatricians determined the Prader genital stage and classified the location of the vaginal entrance into the common urogenital sinus as low, moderate, or high. CYP21A2 gene, coding for 21-hydroxylase, was analyzed with Southern blotting and direct sequencing. Genotypes were categorized into four mutation groups, based on the degree of enzymatic activity (N, complete enzyme inactivation; groups A, < 2%, B, 3-7%, and C > 30%). Basal androgen levels were available from only six out of thirteen patients, so we could not relate androgen levels with the severity of external genitalia virilization. We compared the degree of external genitalia virilization with genotype. The severity of external genitalia virilization varied from Prader stage 1 to 4. One patient who presented with Prader 1 had a genotype consistent with Group B. In addition, discordance between Prader classification and the location of the vaginal entrance was noted; one patient classified as Prader 4 showed low vaginal entrance, while another patient classified as Prader 3 showed high vaginal entrance. The degree of the impairment of 21-hydroxylase activity does not correlate with the severity of virilization of the external genitalia in female patients with the SW type of 21OHD.
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Tohoku J. Exp. Med., 2008, 215 (4) , 341-348. © 2008 Tohoku University Medical Press University Hospital. Their parents were not consanguineous. Diagnosis of CAH was confirmed by clinical, hormonal, and genetic examinations. Criteria for classification into the SW phenotype included history of a salt-losing crisis with documented hyponatremia, hyperkalemia, and markedly elevated plasma renin activity (PRA) (Charmandari et al. 2002) . Electrolyte and hormonal data are shown in Table 1 . All data were obtained before treatment. All patients exhibited high 17OHP with ambiguous genitalia. All patients except Patients 8, 12, and 13 exhibited hyponatremia and hyperkalemia (Table 1) . Treatment for Patient 8 was started since her sibling was affected. Treatments for Patients 12 and 13 were started before the appearance of electrolyte disturbance because of ambiguous genitalia and pigmentation. When Patients 8, 12, and 13 were 12, 8, and 5 years of age, respectively, they showed markedly elevated PRA (28.6, 14.1, and 30.0 ng/ml/hr, respectively) despite being treated with hydrocortisone and fludrocortisone, which indicated that they have SW type of 21OHD. Their karyotypes were 46, XX.
Classification of ambiguous genitalia
The degree of the external genitalia virilization was classified according to Prader stages (Prader and Gurtner 1955) by urologists and pediatricians at Nagoya City University Hospital. Stage 1 refers to the presence of clitoromegaly without labial fusion. Stage 2 is characteristic of clitoromegaly and posterior labial fusion. Stage 3 involves a greater degree of clitoromegaly with almost complete labial fusion and presence of a urogenital sinus. In Stage 4, the clitoris has a phallic appearance, the urethral orifice is at the base of the clitoris, and there is chordee with an otherwise completely fused labial fold. Stage 5 describes a male phenotype due to the penile transformation of the clitoris and urethra, and complete fusion of the labial folds. Table 1 shows the classification of our patients according to Prader stages.
Confluence of urethra and vagina
The level of confluence of the urethra and vagina was classified as low, moderate, or high, as described previously (Rink et al. 2005) . Endoscopic and genitographic evaluations were performed before or at the time of genitoplasty when patient age was 1-3 years.
Hormone assays
Serum 17OHP was analyzed by RIA using a commercial kit (Coat-A-Count, Diagnostic Products Corp., Congenital adrenal hyperplasia (CAH) is one of the most common autosomal recessive disorders resulting from a deficiency of one of the enzymes required for synthesis of cortisol in the adrenal cortex. More than 90% of cases are caused by 21-hydroxylase deficiency (21OHD) (White and Speiser 2000) . Approximately 75% of patients with classic 21OHD have the saltwasting (SW) form (Speiser and White 2003) , which is associated with severe impairment of 21-hydroxylation of progesterone and 17-hydroxyprogesterone (17OHP). Impaired 21-hydroxylase activity causes accumulation of steroid precursors, which then flow into biosynthetic pathways unaffected by the block, resulting in the production of excess androgens. When androgens are over-secreted from the adrenals, the female fetus is virilized. Complete enzyme inactivation or low but measurable enzyme activity leads to SW, 3-7% residual enzyme activity leads to the simple virilizing type (SV), and > 30% residual enzyme activity leads to the non-classic type (NC) (Speiser and White 2003) .
The relationship between genotype and phenotype (SW, SV, and NC), which included Prader stages, have been described previously (Jaaskelainen et al. 1997; Krone et al. 2000; Rocha et al. 2008 ). However, discordance was noted between the phenotype and enzyme activity, which is predicted from the genotype (Bachega et al. 1998) . Therefore, the influence of enzyme activity could not be determined accurately.
We investigated only SW female patients whose phenotype showed that their 21-hydroxylase activity was very low or absent clinically. In this group, we studied variations of external genitalia virilization and, when available, pretreatment androgen levels. We also analyzed the CYP21A2 gene in these patients and investigated correlations between genotype, severity of external genitalia virilization, and basal androgen levels.
PATIENTS AND METHODS

Patients
We studied thirteen Japanese female patients with 21OHD from twelve families, including 1 pair of siblings (Patients 7 and 8). All of them visited Nagoya City Los Angeles, CA) (mean ± SD: 0.41 ± 0.28 ng/ml). Intraassay variation was 3.5-7.1% and interassay variation was 5.0-11%. Plasma ACTH, PRA, serum testosterone, and DHEA-S were determined by standard commercial RIA.
DNA analysis
Molecular investigation of the CYP21A2 gene was performed with the approval of the Institutional Review Board of the Nagoya City University Graduate School of Medical Sciences Institute for Molecular Research, and informed consent was obtained from all patients' families before participation in the CYP21A2 gene studies.
Gene deletions and large gene conversions were detected using Southern blotting. Genomic DNA was prepared from peripheral blood leukocytes by standard procedures (Miller et al. 1988) . DNA was digested with the restriction endonucleases TaqI, BglII, EcoRI, and KpnI. Digestion products were electrophoresed on 1.0% agarose gels and transferred to nylon membranes, and a 2.2-kb BamHI cDNA fragment labeled with [ 32 P]deoxy-CTP by random priming was used as the hybridization probe. Dr. Makoto Ono of the Department of Pediatrics, Tokyo Medical and Dental University, kindly provided cDNA fragments. After autoradiography, the density of DNA bands was determined using an automated densitometer (Maniatis et al. 1982; White et al. 1985; Morel et al. 1989; Mornet et al. 1991; Speiser et al. 1992) .
Direct sequencing of the amplified CYP21A2 gene was performed in patients in whom abnormalities were not identified by Southern blotting, as described previously (Koyama et al. 2002) ; the first PCR amplification was performed using F1-R3 and F3-R8 primer pairs, which are CYP21A2-specific, and second PCR amplification using F1-R1, F2-R2, F3-R3, F4-R4, F5-R5, F6-R6, F7-R7, and F8-R8 primer pairs. Primer sequences are shown in Table 2 . Amplification was performed by initial denaturation at 95°C for 4 min, followed by 30 cycles at 95°C for 30 s for denaturation, 65°C for 30 s for annealing, 72°C for 30 s for elongation, and a final elongation at 72°C for 7 min.
Categorization of mutations and genotypes
Based on the level of enzyme activity predicted from in vitro mutagenesis and expression studies (Higashi et al. 1988; Tusie-Luna et al. 1990; Higashi et al. 1991; Tusie-Luna et al. 1991) , there are two classifications of predicted mutation severity. One involves classification into four groups (Null allele (N) and Groups A to C), as described by Wedell et al. (Wedwell et al. 1994 ) and Speiser et al. (Speiser et al. 1992) . N contains mutations that are established causes of complete enzyme inactivation, Group A contains mutations with residual enzymatic activity (RA) of < 2%, Group B contains mutations with RA of 3-7%, and Group C contains mutations with RA of > 30%. In recent years, Balsamo et al. (Balsamo et al. (Speiser and White 2003) modified this classification into three groups: the first group includes Groups N and A, because they correspond to SW; the second group is Group B, which corresponds to SV; and the last group is Group C, which corresponds to NC. In this study, we used the four-group classification since the small amount of enzyme activity in Group A might have influenced the degree of external genitalia virilization. Group N consists of patients with homozygous or compound heterozygous deletions, large/small conversions, Del8bp, R356W, Q318X, and CluE6. Group A consists of patients with In2 splice (I2g splice) (Wilson et al. 1995) in homozygosity or compound heterozygosity with any of the Group N or A mutations. Group B mutations consist mainly of the missense mutation I172N (Amor et al. 1988 ), R341P and R426H (Barbaro et al. 2006) in homozygosity or compound heterozygosity with any of the Group N, A, or B mutations. Group C includes mutations such as Val281Leu (V281L) (Speiser and New 1987) and Pro30Leu (P30L) (Tusie-Luna et al. 1991) . In addition to these four groups of mutations, five mutations that have, as yet, only been found in one patient or in one pair of siblings were placed in Group D (Wedell et al. 1992; Wedell and Luthman 1993a; Wedell and Luthman 1993b 
RESULTS
External genitalia
One patient was classified as Prader 1, four as Prader 2, five as Prader 3 and three as Prader 4. No patients were classified as Prader 5. Patient 1, who was classified as Prader 1, was investigated because of high 17OHP levels during a mass screening and was subsequently diagnosed. Patient 11, classified as Prader 4, had been registered as a boy at birth and had her social gender changed from male to female when she was aged 6 months. Mass-screening results provided data for diagnosis, and the patient was found to be genetically female. All other patients were investigated because of ambiguous genitalia (Table 3) .
Level of confluence of the urethra and vagina
Based on endoscopic and genitographic evaluations, we classified 8 patients with urogenital sinus into low, moderate, and high groups (Table 1) . Two patients showed high vaginal con- 
Biochemical evaluation
All patients had high values for 17OHP and ACTH. Patients 10 and 11, who showed high vaginal confluence, had 17OHP values (221 and 200 ng/ml, respectively) similar to that of Patient 1 (150 ng/ml). However, Patient 1 showed only mild virilization of her external genitalia (Prader 1) .
The basal testosterone values for Patients 2 and 4 (Prader 2) were 1,430 and 1,370 ng/dl, respectively. The basal testosterone value for Patient 13 was 125 ng/dl; however, her external genitalia virilization was more severe (Prader 4) than that of Patient 2 or 4. The DHEA-S value for Patient 13 was 517 ng/ml. The DHEA-S values for Patients 2, 3, and 4 (all Prader 2) were 1,420, 2,395, and 1,230 ng/ml, respectively. The values for 17-KS overlapped from Prader 1 to 4.
Genetic features
The results of DNA analysis, Prader stage, and vaginal confluence are shown in Table 4 . Four patients had Group N genotype, six had Group A genotype, and one had Group B genotype. There were no patients with Group C genotype, while two patients had Group D genotype.
In Group N, three patients were classified as Prader 2 and one as Prader 3. In Group A, one patient was classified as Prader 2, three as Prader 3, and two as Prader 4. In Group B, one patient was classified as Prader 1. In Group D, one patient was classified as Prader 3 and one as Prader 4. There were no differences between Groups N and A with regard to severity of virilization of external genitalia.
DISCUSSION
Several previous manuscripts have described correlations between genotype and phenotype, which includes Prader stages, in all type of 21OHD patients (Jaaskelainen et al. 1997; Krone et al. 2000; Rocha et al. 2008 ). Jaaskelainen et al. agreed with previous results in that the genotypephenotype correlation in 21OHD is generally rather good. Krone et al. investigated the relationship of Prader stages and mutation groups, which were differentiated according to predicted 
enzyme activity. They mentioned that Prader stages mirrored the severity of the genotype in the groups with the most severe and mildest mutations, and some overlaps in Prader stages were observed in the groups with intermediate severity of mutations. Rocha et al. described clinical forms, Prader stages, and genotypes in Groups N and A, but did not explain the basal androgen levels. Here, we investigated Prader stage, genotype, and androgens only in SW patients. By limiting the study to patients whose clinical form was SW, we were able to evaluate the influence of enzyme inactivation in vivo on virilization of the external genitalia.
The external genitalia of Patient 1 met the criteria for Prader stage 1, which is very mild virilization, and her gene mutation was I172N in Group B; however, she exhibited SW clinically. Even though I172N is associated with a more variable phenotype than the other recurring mutation in CYP21A2 (Jaaskelainen et al. 1997) , this finding is uncommon in the existing literature when we consider Patient 1 as having the SW form. The peripheral sensitivity to androgens, mediated by factors such as local 5-α reductase deficiency or androgen receptor (AR) gene mutations or polymorphisms, might cause individual variation of the external genitalia virilization (Giwercman et al. 2002) . In addition, several authors have investigated some additional mutations of CYP21A2 promoter regions in cases exhibiting some discrepancies in genotype/ phenotype (Araujo et al. 2007) . Further studies analyzing these mutations will explain this discordance of genotype/phenotype.
In humans, the internal and external genitalia develop identically in both sexes up to seven weeks of gestation. Ambiguous genitalia are formed by exposure to high levels of adrenal androgens from approximately the seventh week of gestation (Sobel et al. 2004 ). In the classical pathway of steroidogenesis from cholesterol, testosterone is converted in target tissues to dihydrotestosterone. A key step in the classical pathway is the conversion of 17α -hydroxypregnenolone to dehydroepiandrosterone (DHEA), which is then converted to androstenedione and further to testosterone and dihydrotestosterone. In recent years, an alternative route to potent androgens has been elucidated. This route does not involve the generation of DHEA, previously assumed to be the "mother steroid" of all sex steroid biosynthesis.
Some authors have shown the existence of a backdoor pathway in the human fetal adrenal gland (Arlt et al. 2004; Fukami et al. 2006; Homma et al. 2006 ). There are two options for 17OHP: 5α -reduction and entry into the backdoor (Hanley and Arlt 2006) . In the present study, high values for testosterone and DHEA-S were not always associated with marked virilization of the external genitalia, which supports the predominance of the backdoor pathway. Unfortunately, we were not able to measure the steroids 5α -pregnane-17α -ol-3, 20-dione, 5α -pregnane-3α , 17α -diol-20-one, androsterone, and androstanediol, which are generated in the backdoor pathway. Bachega et al. (1998) observed a good correlation of genotype with testosterone and androstenedione levels and concluded that the intensity of hyperandrogenism was correlated with the severity of neonatal genitalia virilization found in Groups N and A. In contrast, Rocha et al. (2008) did not observe a correlation between basal testosterone levels and the degree of external genitalia virilization. Although basal androgen levels were available in only six out of thirteen patients, our data did not show a clear relationship between the severity of external genitalia virilization and androgens. Our data, and that of Rocha et al., may suggest that high values of androgens and 17OHP are not necessarily related to marked virilization of the external genitalia. In addition, the severity of external genitalia virilization in our patients varied markedly, from Prader 1 to 4, despite all subjects having the SW type of 21OHD. Hormonal data obtained after birth may not reflect the androgen levels at around the seventh week of gestation. These observations show that enzyme activity is not the only factor deciding the severity of external genitalia virilization in female 21OHD patients, even those with the SW type.
In summary, female SW 21OHD patients did not necessarily show marked virilization of the external genitalia. The degree of external genitalia virilization varied from Prader stage 1 to 4 in SW patients. The severity of external genitalia virilization was not correlated with CYP21A2 activity even in the genotype of Groups N and A. We were not able to identify a clear relationship between basal androgen levels after birth and external genitalia virilization. Residual CYP21A2 activity was not the only factor predicting the severity of virilization of external genitalia in female SW 21OHD patients. These data suggest that impairment of CYP21A2 activity is involved in virilization of the external genitalia and do not determine the degree of virilization.
